198 related articles for article (PubMed ID: 19896233)
1. Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: a retrospective database analysis.
Lee LJ; Yu AP; Johnson SJ; Birnbaum HG; Atanasov P; Buesching DP; Jackson JA; Davidson JA
Diabetes Res Clin Pract; 2010 Jan; 87(1):108-16. PubMed ID: 19896233
[TBL] [Abstract][Full Text] [Related]
2. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
[TBL] [Abstract][Full Text] [Related]
3. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products.
Bullano MF; Al-Zakwani IS; Fisher MD; Menditto L; Willey VJ
Curr Med Res Opin; 2005 Feb; 21(2):291-8. PubMed ID: 15802000
[TBL] [Abstract][Full Text] [Related]
4. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study.
Schöffski O; Breitscheidel L; Benter U; Dippel FW; Müller M; Volk M; Pfohl M
J Med Econ; 2008; 11(4):695-712. PubMed ID: 19450076
[TBL] [Abstract][Full Text] [Related]
5. Comparison of incidence of acute myocardial infarction in patients with type 2 diabetes mellitus following initiation of neutral protamine Hagedorn insulin versus insulin glargine.
Rhoads GG; Kosiborod M; Nesto RW; Fonseca VA; Lu SE; Zhang Q; Foody JM
Am J Cardiol; 2009 Oct; 104(7):910-6. PubMed ID: 19766755
[TBL] [Abstract][Full Text] [Related]
6. Lower severe hypoglycemia risk: insulin glargine versus NPH insulin in type 2 diabetes.
Dailey G; Strange P
Am J Manag Care; 2008 Jan; 14(1):25-30. PubMed ID: 18197742
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials.
Bazzano LA; Lee LJ; Shi L; Reynolds K; Jackson JA; Fonseca V
Diabet Med; 2008 Aug; 25(8):924-32. PubMed ID: 18959605
[TBL] [Abstract][Full Text] [Related]
8. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study.
Fischer JS; McLaughlin T; Loza L; Beauchamp R; Schwartz S; Kipnes M
Curr Med Res Opin; 2004 Nov; 20(11):1703-10. PubMed ID: 15537471
[TBL] [Abstract][Full Text] [Related]
9. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
Clin Ther; 2007 Jun; 29(6 Pt 1):1294-305. PubMed ID: 18036391
[TBL] [Abstract][Full Text] [Related]
10. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus.
Cobden D; Lee WC; Balu S; Joshi AV; Pashos CL
Pharmacotherapy; 2007 Jul; 27(7):948-62. PubMed ID: 17594200
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy.
Yokoyama H; Tada J; Kamikawa F; Kanno S; Yokota Y; Kuramitsu M
Diabetes Res Clin Pract; 2006 Jul; 73(1):35-40. PubMed ID: 16513202
[TBL] [Abstract][Full Text] [Related]
12. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies.
Xie L; Wei W; Pan C; Baser O
J Med Econ; 2013 Sep; 16(9):1137-45. PubMed ID: 23859434
[TBL] [Abstract][Full Text] [Related]
13. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization.
Cooke CE; Lee HY; Tong YP; Haines ST
Curr Med Res Opin; 2010 Jan; 26(1):231-8. PubMed ID: 19921965
[TBL] [Abstract][Full Text] [Related]
14. Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes.
Päivärinta M; Tapanainen P; Veijola R
Pediatr Diabetes; 2008 Jun; 9(3 Pt 2):83-90. PubMed ID: 18221431
[TBL] [Abstract][Full Text] [Related]
15. Insulin glargine for type 2 diabetes.
Hemraj F; Garces K
Issues Emerg Health Technol; 2004 Aug; (59):1-4. PubMed ID: 15311441
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of insulin glargine vs. neutral protamine Hagedorn insulin in type 2 diabetes: a focus on health economics.
Levin P
Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():66-75. PubMed ID: 18577158
[TBL] [Abstract][Full Text] [Related]
17. Early retinopathy progression in four randomized trials comparing insulin glargine and NPH [corrected] insulin.
Davis MD; Beck RW; Home PD; Sandow J; Ferris FL
Exp Clin Endocrinol Diabetes; 2007 Apr; 115(4):240-3. PubMed ID: 17479440
[TBL] [Abstract][Full Text] [Related]
18. Initiation of insulin glargine in children and adolescents with type 1 diabetes.
Tan CY; Wilson DM; Buckingham B
Pediatr Diabetes; 2004 Jun; 5(2):80-6. PubMed ID: 15189493
[TBL] [Abstract][Full Text] [Related]
19. Insulin glargine maintains equivalent glycemic control and better lipometabolic control than NPH insulin in type 1 diabetes patients who missed a meal.
Rosak C; Jung R; Hofmann U
Horm Metab Res; 2008 Aug; 40(8):544-8. PubMed ID: 18493882
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the subcutaneous absorption of insulin glargine (Lantus) and NPH insulin in patients with Type 2 diabetes.
Luzio SD; Beck P; Owens DR
Horm Metab Res; 2003 Jul; 35(7):434-8. PubMed ID: 12931275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
